Skip to content

Study · Animal study (in vivo) · mouse · 2008

3 results

Peptidergic agonists of activity-dependent neurotrophic factor protect against prenatal alcohol-induced neural tube defects and serotonin neuron loss.

Zhou FC, Fang Y, Goodlett C

Alcoholism, clinical and experimental research28 Jun 2008Cited by 18 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In alcohol-exposed mouse pregnancies, NAP protected less effectively against fetal dysraphia than SAL.

    In plain wordsIn mice exposed to alcohol during pregnancy, NAP protected less against neural tube defects than SAL.

    Peptide
    Davunetide
    Outcome
    DecreaseProtection against dysraphia
    Study

    Mousen: not reported in source

    Prenatal alcohol exposure in B6 mice
    Comparator
    SAL
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · Daily from E7 to E15As given in this study (Mouse).

    Source sentences

    Summary
    NAP was less effective in protecting against dysraphia and did not protect against 5-HT loss in the rostral raphe, but did protect against loss in the caudal raphe.
    2 context sentences
    Summary · context
    Timed-pregnant B6 dams consumed alcohol from embryonic day 7 (E7, before the onset of neurulation) until E15.
    Summary · context
    Additional groups were treated either with SAL or NAP daily from E7 to E15 to assess the potential protective effects of these peptides.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In alcohol-exposed mouse pregnancies, NAP did not protect against fetal rostral raphe serotonin neuron loss.

    In plain wordsIn mice exposed to alcohol during pregnancy, NAP did not protect against serotonin neuron loss in the rostral raphe.

    Peptide
    Davunetide
    Outcome
    Not applicableRostral raphe serotonin neuron loss
    Study

    Mousen: not reported in source

    Prenatal alcohol exposure in B6 mice
    Comparator
    Alcohol exposure without peptide treatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · Daily from E7 to E15As given in this study (Mouse).

    Source sentences

    Summary
    NAP was less effective in protecting against dysraphia and did not protect against 5-HT loss in the rostral raphe, but did protect against loss in the caudal raphe.
    2 context sentences
    Summary · context
    Timed-pregnant B6 dams consumed alcohol from embryonic day 7 (E7, before the onset of neurulation) until E15.
    Summary · context
    Additional groups were treated either with SAL or NAP daily from E7 to E15 to assess the potential protective effects of these peptides.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In alcohol-exposed mouse pregnancies, NAP protected against fetal caudal raphe serotonin neuron loss.

    In plain wordsIn mice exposed to alcohol during pregnancy, NAP protected against serotonin neuron loss in the caudal raphe.

    Peptide
    Davunetide
    Outcome
    DecreaseCaudal raphe serotonin neuron loss
    Study

    Mousen: not reported in source

    Prenatal alcohol exposure in B6 mice
    Comparator
    Alcohol exposure without peptide treatment
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · Daily from E7 to E15As given in this study (Mouse).

    Source sentences

    Summary
    NAP was less effective in protecting against dysraphia and did not protect against 5-HT loss in the rostral raphe, but did protect against loss in the caudal raphe.
    2 context sentences
    Summary · context
    Timed-pregnant B6 dams consumed alcohol from embryonic day 7 (E7, before the onset of neurulation) until E15.
    Summary · context
    Additional groups were treated either with SAL or NAP daily from E7 to E15 to assess the potential protective effects of these peptides.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.